MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights:Net sales were $2.4 million, a 26% increase compared to the prior-year period Gross margin improved to 70.1%, reflecting improved pricing, product mix, and the transition to contract manufacturing Completed the acquisition of Rendiatech, adding automated kidney-function monitoring capabilities to the Company’s product development portfolio Appointed Carisa Schultz as Chief Financial Officer and Dr. Stuart L. Goldstein as Director of Clinical Strategy Appointed Martin J. Emerson and reappointed David A. McDonald to the Board of Directors Expanded...

Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701 Announced presentation of updated CRB-701 data in HNSCC and cervical cancer at ASCO 2026 Completed enrollment in 16-week study CANYON-1 study (n=240) of CRB-913 for the treatment of obesity with topline data on track to report this summerNORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 first quarter ended March 31, 2026.  “We’ve continued to build strong momentum with CRB-701 and CRB-913, setting the...

Higher Gross Margins Reflect Strategic Shift to Recurring Merchandising RevenueCompany Reiterates Full-Year Financial Guidance CHARLOTTE, N.C., May 12, 2026 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SGRP”, and together with its subsidiaries, “SPAR,” “SPAR Group” or the “Company”), an innovative services company offering comprehensive merchandising and marketing solutions for retailers and brands throughout the United States and Canada, today reported financial results for the period ended March 31, 2026. William Linnane, President and Chief Executive Officer of SPAR Group, commented, “I am pleased to report that SPAR returned to positive EBITDA and delivered substantially higher gross margins than the prior year.   Though revenue was down year-on-year, driven by a decline in our US Remodel business, we were pleased to...

Q1’26 Revenue $72.8 million Q1’26 Op Inc ($12.9) million loss due to revenue miss and staffing for Q3’26 growth Convertible note offering reduced debt by $40 million Bookings increased to a record 4,446 jobs, up from 1,197 in Q1’25 due to acquisitions 2025 10K statement filed on time; difficult 10K audit We plan to file the Q1’25-Q3’25 10Q restatements on timeOREM, Utah, May 12, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (herein “SunPower,” the “Company,” or Nasdaq: “SPWR”), a solar technology, services, and installation company, will present its Q1’26 results via webcast today, Tuesday, May 12, at 1:00pm ET. Register for the webcast here or by visiting our Events page: https://investors.sunpower.com/news-events/events. Fellow Shareholders:The preliminary, unaudited Q1’26 report is shown below, compared to the Q4’25 results from...

LAS VEGAS, May 12, 2026 (GLOBE NEWSWIRE) — TON Strategy Company (“TON Strategy” or the “Company”) (Nasdaq: TONX), a digital asset treasury company dedicated to holding Toncoin ($TON), today reported financial results for the first quarter ended March 31, 2026 and provided an update on its TON treasury operations. First Quarter and Recent Operational HighlightsHeld approximately 221.9 million units of $TON at March 31, 2026, including approximately 221.2 million units staked. Based on Tonstat data, the Company’s holdings represented approximately 4.29% of all Toncoin, and the Toncoin staked through its infrastructure represented approximately 26.18% of the network. Digital assets held at March 31, 2026 had a fair value of approximately $272.0 million. Earned approximately 2.2 million units of $TON during the first quarter of 2026,...

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across...

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the first quarter ended March 31, 2026 and provided business updates. “I am happy to report that new batches...

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumors Rezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 Cash, cash equivalents, and marketable securities of $93.5 million as of March 31, 2026 providing expected cash runway to end of second quarter of 2027PRINCETON, N.J., May 12, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the first...